Shock and Acute Conditions OutcOmes Platform

Summary

In-hospital mortality of patients admitted in the intensive care unit (ICU) for circulatory shock remains high (between 20 and 40%).

Currently, there are no markers that allow us to classify patients with circulatory shock at higher risk of early and late bad outcomes, or who may better respond to a specific intervention.

To understand the contribution of biological heterogeneity to circulatory shock independently from its etiology, the ShockCO-OP Research Program aims to use clustering approaches to re-analyze existing clinical and molecular data from several large European and North American prospective cohorts and clinical trials.

This will enable an improvement in risk prediction and a better patient selection in future clinical trials to assess a personalized therapy (i.e., prospective enrollment based on a biological/molecular signature).

Conditions

• Circulatory Shock
• Sepsis
• Cardiogenic Shock
• Major Trauma
• Surgical Shock

Interventions

DRUG

Inotrope

Vasopressors: Norepinephrine, vasopressin Inotropes: Epinephrine, Dobutamine, Milrinone

DEVICE

Mechanical circulatory support

Intra-aortic balloon pump Extracorporeal membrane oxygenation (ECMO)

DRUG

anti-bodies

Anti-Dipeptidyl peptidase 3 (DPP3), Anti-Bioactive adrenomedullin (bio-ADM)

Sponsors & Collaborators

• University of Helsinki

  collaborator OTHER

• University of Ottawa

  collaborator OTHER

• University of Leipzig

  collaborator OTHER

• University of Nancy

  collaborator OTHER

• McGill University

  collaborator OTHER

• Mayo Clinic

  collaborator OTHER

• University of Paris 5 - Rene Descartes

  collaborator OTHER

• University of Toronto

  collaborator OTHER

• Saint-Louis Hospital, Paris, France

  lead OTHER

Principal Investigators

• Claudia dos Santos, MD, PhD · Unity Health Toronto

• Alexandre Mebazaa, MD, PhD · St Louis and Lariboisiere Hospitals

Eligibility

Min Age

18 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-01-01

Primary Completion

2025-07-01

Completion

2026-01-01

Countries

• Canada

Study Locations